Litcius/Paper detail

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

David A. Sallman, Tessa Kerre, Violaine Havelange, Xavier Poiré, Philippe Lewalle, Eunice S. Wang, Jason Brayer, Marco L. Davila, Ine Moors, Jean‐Pascal Machiels, Ahmad Awada, Erik Alcantar-Orozco, Rossitza Borissova, Nathalie Braun, Marie-Sophie Dheur, David E. Gilham, Caroline Lonez, Frédéric Lehmann, Anne Flament

2023The Lancet Haematology93 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMyelodysplastic syndromesInternal medicineOncologyMultiple myelomaPhases of clinical researchPopulationClinical endpointClinical trialGastroenterologyBone marrowEnvironmental healthCAR-T cell therapy researchImmune Cell Function and InteractionLymphoma Diagnosis and Treatment
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial | Litcius